Stock itci.

$-1.63 Market Cap $5.46 B Shares Outstanding 96.24 M Public Float 93.82 M Yield ITCI is not currently paying a regular dividend. Latest Dividend N/A Ex-Dividend Date N/A Short Interest (10/31/23)...

Stock itci. Things To Know About Stock itci.

IntraCellular Therapies (ITCI) (Delayed Data from NSDQ) $61.37 USD +1.94 (3.26%) Updated Nov 30, 2023 04:00 PM ET After-Market: $61.37 0.00 (0.00%) 4:48 PM …Oct 26, 2023 · Intra-Cellular Therapies Inc’s trailing 12-month revenue is $365.8 million with a -50.4% profit margin. Year-over-year quarterly sales growth most recently was 99.3%. Analysts expect adjusted earnings to reach $-2.089 per share for the current fiscal year. Intra-Cellular Therapies Inc does not currently pay a dividend. IntraCellular Therapies (ITCI) Quote Overview » More Research » IntraCellular Therapies (ITCI) Full Company Report Better trading starts here. Company SummaryEarnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($1.68) to ($0.80) per share. Intra-Cellular Therapies has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 6th, 2024 based off prior year's report dates. Read More.Mar 6, 2023 · Read why ITCI stock is a Hold. Intra-Cellular Therapeutics develops small molecule drugs targeting the CNS for neuropsychiatric and neurological disorders. Read why ITCI stock is a Hold.

Intra-Cellular Therapies Inc. stock grades by Barron's. View ITCI fundamental and sentiment analysis powered by MarketGrader.Zacks Investment Research is releasing its prediction for ITCI based on the 1-3 month trading system that more than doubles the S&P 500. Click here - the ITCI analysis is free ». Price. 2021 ...NEW YORK, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the completion of its previously announced underwritten public offering of 9,523,810 shares of its common …

The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $78.67. ITCI has been the topic of a number of research analyst reports. Needham & Company LLC lifted their target price on Intra-Cellular Therapies from $71.00 to $72.00 and gave the stock a “buy” rating in a report on Friday ...The 13 analysts offering 1 year price forecasts for ITCI have a max estimate of — and a min estimate of —. Analyst rating Based on 13 analysts giving stock ratings to ITCI in the past 3 months.

NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, …Aug 4, 2023 · As of Jun 30, 2023, ITCI had cash, cash equivalents, restricted cash and investment securities of $514.6 million compared with $540.5 million as of Mar 31, 2023. 2023 Guidance Updated NEW YORK Dec. 06 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies Inc. (Nasdaq:ITCI) a biopharmaceutical company focused on the development. NEW YORK Dec. 06 2021 (GLOBE NEWSWIRE) -- Intra ... home / stock / itci / itci news. RSS . ITCI ITCI Quote ITCI Short ITCI News ITCI Articles ITCI Message Board. December, 06 2021 …Intra-Cellular Therapies (ITCI) closed the last trading session at $51.22, gaining 6.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets ...

TipRanks | Stock Market Research, News and Analyst Forecasts ...

Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.

Get up to 10 years of daily historical stock prices & volumes. The "Close/Last" is the “adjust consolidated close price”. Data provided by Edgar Online. The net and percent change in the quote ...Our Mission. Our mission is to deliver innovative treatments to improve the lives of individuals with neuropsychiatric, neurologic, and other disorders to reduce the burden on patients and their caregivers.Future criteria checks 6/6. Intra-Cellular Therapies is forecast to grow earnings and revenue by 73.1% and 32.2% per annum respectively. EPS is expected to grow by 71.8% per annum. Return on equity is forecast to be 31.1% in 3 years.NEW YORK, April 16, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, mourns the passing of our co-founder, Dr. Paul Greengard, a neuroscientist and Nobel Laureate whose pioneering research …ITCI stock rallied 2.2% Friday. Inspire Medical Systems ( INSP ) posted a weekly gain despite three losing days, gaining 3.8% Friday. INSP shares formed a handle and flirted with the 277.28 buy ...

Dec 1, 2023 · The average price recommended by analysts for Intra-Cellular Therapies Inc (ITCI) is $77.54, which is $16.26 above the current market price. The public float for ITCI is 93.65M and currently, short sellers hold a 3.65% of that float. On December 01, 2023, ITCI’s average trading volume was 845.52K shares. Top 5 EV Tech Stocks to Buy for 2023. Wall Street Analysts Think Intra-Cellular (ITCI) Could Surge 33.02%: Read This Before Placing a Bet. The mean of analysts' price targets for Intra-Cellular (ITCI) points to a 33% …Join Our Free Stock Market Newsletter: StockMarket.com is the #1 resource for all things Stocks. Sign up today for Free!ITCI Stock Overview. Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system …Tsai is hardly the only bull on this stock; ITCI has a unanimous Strong Buy consensus rating supported by 9 analyst reviews. The average price target of $68.67 gives a 12% upside potential from the current share price of $61.05. (See ITCI stock analysis on TipRanks)Mar 28, 2023 · 04:20 PM ET 03/28/2023. Intra-Cellular Therapies ( ITCI) said Tuesday that its depression treatment succeeded in a key study, and ITCI stock broke definitively above its 200-day line for the first ...

2 Wall Street research analysts have issued twelve-month price objectives for Nano-X Imaging's shares. Their NNOX share price targets range from $14.50 to $30.00. On average, they anticipate the company's stock price to reach $22.25 in the next year. This suggests a possible upside of 253.7% from the stock's current price.Intra-Cellular: Q1 Earnings Snapshot. NEW YORK (AP) — NEW YORK (AP) — Intra-Cellular Therapies Inc. (ITCI) on Thursday reported a loss of $44.1 million in its first quarter. The New York-based company said it had a loss of 46 cents per share. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by ...

Nov 27, 2022 · Headquartered in Chelmsford, Massachusetts, Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) is a sample exploration and management solutions provider for the life science market. On November 23, 2022 ... A high-level overview of Intra-Cellular Therapies, Inc. (ITCI) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and …ITCI Earnings Date and Information. Intra-Cellular Therapies last released its quarterly earnings results on November 2nd, 2023. The biopharmaceutical company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.34. The business earned $126.17 million during the quarter, compared to the consensus estimate of ...May 4, 2023 · Intra-Cellular: Q1 Earnings Snapshot. NEW YORK (AP) — NEW YORK (AP) — Intra-Cellular Therapies Inc. (ITCI) on Thursday reported a loss of $44.1 million in its first quarter. The New York-based company said it had a loss of 46 cents per share. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by ... As of Jun 30, 2023, ITCI had cash, cash equivalents, restricted cash and investment securities of $514.6 million compared with $540.5 million as of Mar 31, 2023. 2023 Guidance UpdatedIn terms of how INTRA-CELLULAR THERAPIES INC fares relative to Pharmaceutical Products stocks, note that its average analyst price target is higher than 3826.61% of that group. ITCI has a greater number of analysts covering the stock than 3418.44% of stocks in the mid market cap category.Complete Intra-Cellular Therapies Inc. stock information by Barron's. View real-time ITCI stock price and news, along with industry-best analysis. ITCI has a Quality Grade of D, ranking ahead of 18.25% of graded US stocks. ITCI's asset turnover comes in at 0.08 -- ranking 278th of 682 Pharmaceutical Products stocks. …

The past 20 months have been good for growth stocks, to say the least. In that time, the S&P 500 just about doubled, while the NASDAQ has done even better, gaining 125%. Corporate earnings ...

Nov. 08. CI. RBC Trims Price Target on Intra-Cellular Therapies to $76 From $77, Keeps Outperform Rating. Nov. 03. MT. Earnings Flash (ITCI) INTRA-CELLULAR THERAPIES Reports Q3 Revenue $126.2M. Nov. 02. MT. Transcript : Intra-Cellular Therapies, Inc., Q3 2023 Earnings Call, Nov 02, 2023.

In a report released on April 6, Brian Abrahams from RBC Capital maintained a Buy rating on Intra-Cellular Therapies ( ITCI – Research Report ), with a price target of $72.00. The company’s ...Intra-Cellular Therapies Inc (ITCI) Intra-Cellular Therapies is a biopharmaceutical company focused on the discovery, clinical development and commercialization of small molecule drugs that address medical needs mainly in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system.The average twelve-month price prediction for Intra-Cellular Therapies is $78.67 with a high price target of $101.00 and a low price target of $62.00. Learn more on ITCI's analyst rating history. Do Wall Street analysts like Intra-Cellular Therapies more than its competitors?The company increased its Caplyta net product sales in the range of $445-$465 million (previously $430-$455 million) for the full-year 2023. Intra-Cellular, however, maintained its full-year 2023 ...ITCI stock shot up to approximately $55 per share after the success of study 403. There is some overhead supply to work through to reach new all-time highs and continued strong sales momentum ...The mean of analysts' price targets for Intra-Cellular (ITCI) points to a 33% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong …What are the best stocks to buy? Learn how you can make that decision for yourself at InvestorPlace. With the help of experienced financial advisors, InvestorPlace can give you the info you need to form an effective investment strategy. So ...Shares of Intra-Cellular Therapies (ITCI) have gained 7.7% over the past four weeks to close the last trading session at $56.01, but there could still be a solid upside left in the stock if short ...ITCI Profile Stock Screener Earnings Calendar Sectors Nasdaq | ITCI U.S.: Nasdaq Intra-Cellular Therapies Inc. Watch list NEW Set a price target alert After Hours Last Updated: Nov 17, 2023... Nov 28, 2023 · Zacks Investment Research is releasing its prediction for ITCI based on the 1-3 month trading system that more than doubles the S&P 500. Click here - the ITCI analysis is free ». Price. 2021 ... Discover historical prices for ITCI stock on Yahoo Finance. View daily, weekly or monthly format back to when Intra-Cellular Therapies, Inc. stock was issued. Find the latest Financials data for Intra-Cellular Therapies Inc. Common Stock (ITCI) at Nasdaq.com.

Intra-Cellular Therapies Inc (ITCI) Intra-Cellular Therapies is a biopharmaceutical company focused on the discovery, clinical development and commercialization of small molecule drugs that address medical needs mainly in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system.Wasatch Global Investors highlighted stocks like Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) in its Q3 2022 investor letter. Headquartered in New York, New York, Intra-Cellular Therapies, Inc ...Intra-Cellular Therapies Inc. analyst ratings, historical stock prices, earnings estimates & actuals. ITCI updated stock price target summary. February 22, 2023 at 10:00 AM · 5 min read. The market expects Intra-Cellular Therapies (ITCI) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the ...Instagram:https://instagram. amc stock buy or sellhow to invest in lithiumsmall nuclear reactor companies stockalnylam pharmaceuticals inc. Our Mission. Our mission is to deliver innovative treatments to improve the lives of individuals with neuropsychiatric, neurologic, and other disorders to reduce the burden on patients and their caregivers.The mean of analysts' price targets for Intra-Cellular (ITCI) points to a 41.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement ... novocure stock pricenasdaq avav Nov 27, 2023 · A high-level overview of Intra-Cellular Therapies, Inc. (ITCI) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. When picking the best stocks under $10 to buy, it's important to identify fundamentally strong and non-speculative stocks. These are fundamentally strong and non-speculative stocks that are under $10 Since the meme stock euphoria in 2020, i... reit best dividend TipRanks | Stock Market Research, News and Analyst Forecasts ...You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.See the latest Intra-Cellular Therapies Inc stock price (NASDAQ:ITCI), related news, valuation, dividends and more to help you make your investing decisions.